Aurobindo Pharma Limited (AUROPHARMA) - Total Assets

Latest as of March 2026: Rs585.02 Billion INR ≈ $6.33 Billion USD

Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) holds total assets worth Rs585.02 Billion INR (≈ $6.33 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Aurobindo Pharma Limited to assess the company's total reinvestment commitment from operating cash flow.

Aurobindo Pharma Limited - Total Assets Trend (2004–2026)

This chart illustrates how Aurobindo Pharma Limited's total assets have evolved over time, based on quarterly financial data. Explore Aurobindo Pharma Limited (AUROPHARMA) investment intensity to see how much of total assets are deployed in long-term investments.

Aurobindo Pharma Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

Aurobindo Pharma Limited's total assets of Rs585.02 Billion consist of 55.9% current assets and 44.1% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 16.9%
Accounts Receivable Rs71.12 Billion 12.2%
Inventory Rs120.53 Billion 20.6%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs44.81 Billion 7.7%
Goodwill Rs8.00 Billion 1.4%

Asset Composition Trend (2004–2026)

This chart illustrates how Aurobindo Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aurobindo Pharma Limited (AUROPHARMA) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Aurobindo Pharma Limited's current assets represent 55.9% of total assets in 2026, an increase from 51.4% in 2004.
  • Cash Position: Cash and equivalents constituted 16.9% of total assets in 2026, up from 3.3% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 1.0% in 2004.
  • Asset Diversification: The largest asset category is inventory at 20.6% of total assets.

Aurobindo Pharma Limited Competitors by Total Assets

Key competitors of Aurobindo Pharma Limited based on total assets are shown below.

Company Country Total Assets
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.69 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Bausch Health Companies Inc
TO:BHC
Canada CA$24.50 Billion
Dezhan HealthCare Co Ltd
SHE:000813
China CN¥4.80 Billion
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
China CN¥8.59 Billion
Hainan Haiyao Co Ltd
SHE:000566
China CN¥5.79 Billion
Shanxi Zhendong Pharmaceutical
SHE:300158
China CN¥4.51 Billion

Aurobindo Pharma Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.81 1.85 1.86
Quick Ratio 1.15 1.13 1.01
Cash Ratio 0.00 0.56 0.00
Working Capital Rs146.70 Billion Rs124.80 Billion Rs91.58 Billion

Aurobindo Pharma Limited - Advanced Valuation Insights

This section examines the relationship between Aurobindo Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.20
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 17.5%
Total Assets Rs585.02 Billion
Market Capitalization $9.32 Billion USD

Valuation Analysis

Below Book Valuation: The market values Aurobindo Pharma Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Aurobindo Pharma Limited's assets grew by 17.5% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Aurobindo Pharma Limited (2004–2026)

The table below shows the annual total assets of Aurobindo Pharma Limited from 2004 to 2026.

Year Total Assets Change
2026-03-31 Rs585.02 Billion
≈ $6.33 Billion
+17.51%
2025-03-31 Rs497.85 Billion
≈ $5.38 Billion
+10.46%
2024-03-31 Rs450.72 Billion
≈ $4.87 Billion
+12.99%
2023-03-31 Rs398.90 Billion
≈ $4.31 Billion
+17.59%
2022-03-31 Rs339.22 Billion
≈ $3.67 Billion
+0.20%
2021-03-31 Rs338.54 Billion
≈ $3.66 Billion
+17.03%
2020-03-31 Rs289.28 Billion
≈ $3.13 Billion
+9.35%
2019-03-31 Rs264.54 Billion
≈ $2.86 Billion
+25.37%
2018-03-31 Rs211.01 Billion
≈ $2.28 Billion
+29.86%
2017-03-31 Rs162.49 Billion
≈ $1.76 Billion
+2.07%
2016-03-31 Rs159.20 Billion
≈ $1.72 Billion
+23.27%
2015-03-31 Rs129.14 Billion
≈ $1.40 Billion
+36.09%
2014-03-31 Rs94.90 Billion
≈ $1.03 Billion
+30.39%
2013-03-31 Rs72.78 Billion
≈ $787.07 Million
+16.68%
2012-03-31 Rs62.38 Billion
≈ $674.58 Million
+6.22%
2011-03-31 Rs58.72 Billion
≈ $635.06 Million
+22.56%
2010-03-31 Rs47.91 Billion
≈ $518.16 Million
+13.36%
2009-03-31 Rs42.26 Billion
≈ $457.08 Million
+16.29%
2008-03-31 Rs36.34 Billion
≈ $393.06 Million
+3.65%
2007-03-31 Rs35.06 Billion
≈ $379.21 Million
+30.38%
2006-03-31 Rs26.89 Billion
≈ $290.85 Million
+26.28%
2005-03-31 Rs21.30 Billion
≈ $230.33 Million
+14.14%
2004-03-31 Rs18.66 Billion
≈ $201.79 Million
--

About Aurobindo Pharma Limited

NSE:AUROPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$9.32 Billion
Rs861.80 Billion INR
Market Cap Rank
#2376 Global
#94 in India
Share Price
Rs1497.80
Change (1 day)
+3.75%
52-Week Range
Rs1022.20 - Rs1517.50
All Time High
Rs1568.05
About

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more